PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Grant revenue | 57,480 | 278,628 | 109,745 | 254,991 |
| Research and development | 867,345 | 388,810 | 413,987 | 472,927 |
| General and administrative | 990,863 | 987,759 | 651,486 | 576,918 |
| Total operating expenses | 1,858,208 | 1,376,569 | 1,065,473 | 1,049,845 |
| Total operating loss | -1,800,728 | -1,097,941 | -955,728 | -794,854 |
| Interest expense | -51,353 | -63,661 | -58,679 | -61,295 |
| Research and development credit | - | - | 56 | - |
| Net loss | -1,852,081 | -1,161,602 | - | - |
| Net loss attributable to noncontrolling interest | -37,661 | -21,494 | - | - |
| Researchanddevelopmenttaxcredit | - | - | - | -9,301 |
| Nonoperating income (expense) | - | - | -58,623 | -51,994 |
| Net loss attributable to common stockholders | -1,814,420 | -1,140,108 | -1,014,351 | -846,848 |
| Basic loss per common share | - | - | - | - |
| Diluted loss per common share | - | - | - | - |
| Weighted average number of common shares outstanding - basic | 420,279,879 | 420,279,879 | 419,906,732 | 419,522,119 |
| Weighted average number of common shares outstanding - diluted | 420,279,879 | 420,279,879 | 419,906,732 | 419,522,119 |